Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05675306 · ClinicalTrials.gov registry record · NA
Dose Frequency RCT on DTTC in Children With CAS
A NA study of Childhood Apraxia of Speech, sponsored by Marquette University.
- Active
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05675306: Active NA study of Childhood Apraxia of Speech, sponsored by Marquette University.
NCT05675306 is a NA study of Childhood Apraxia of Speech that is active but no longer recruiting, run by Marquette University. The registered enrollment target is 60 participants, below the 177-participant average among 3 other Childhood Apraxia of Speech trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05675306, a NA study of Childhood Apraxia of Speech, is active but no longer recruiting, sponsored by Marquette University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Childhood apraxia of speech (CAS) is a pediatric motor-based speech sound disorder that requires a specialized approach to intervention (Maas et al., 2014). The extant literature on the treatment of CAS commonly recommends intensive treatment using a motor-based approach, with some of the best evidence supporting the use of Dynamic Temporal and Tactile Cueing (DTTC; Strand, 2020). To date, a rigorous and systematic comparison of high and low dose frequency has not been undertaken for DTTC, resulting in a lack of evidence to guide decisions about the optimal treatment schedule for this intervention. The current study aims to fill this gap in knowledge by comparing treatment outcomes when dose frequency is varied. The goal of this clinical trial is to determine whether the number of treatment sessions per week has an effect on intervention outcomes in 60 children with CAS. The main question this research will address is whether whole word accuracy will differ between two groups of children undergoing DTTC treatment when one group of children receives treatment twice a week for 12 weeks and the other group receives treatment 4 times a week for 6 weeks. Community clinicians will administer all treatment sessions.
Primary Outcome
A multi-factor whole word accuracy measure (Multilevel word Accuracy Composite Scale; Case et al., under review) that systematically accounts for segmental and prosodic accuracy, word shape maintenance, and smoothness and fluency of movement transitions will be calculated on treated and similar untreated words in the generalization probe.
Conditions Studied
Interventions
- BEHAVIORAL Dynamic Temporal and Tactile Cueing Treatment
Study Locations (1)
Wisconsin
- Marquette U - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What the registry record for NCT05675306 still lists
NCT05675306 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 177-participant average among 3 other Childhood Apraxia of Speech trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Childhood Apraxia of Speech appearing as the primary indexed condition, and to 1 intervention - of which Dynamic Temporal and Tactile Cueing Treatment is the first listed.
NCT05675306 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05675306 about?
NCT05675306 is a clinical study titled "Dose Frequency RCT on DTTC in Children With CAS". Childhood apraxia of speech (CAS) is a pediatric motor-based speech sound disorder that requires a specialized approach to intervention (Maas et al., 2014). The extant literature on the treatment of CAS commonly recommends intensive treatment using a motor-based approach, with some of the best evide...
What is the current status of trial NCT05675306?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2023-03-01. Estimated completion is 2025-12-31.
What conditions does trial NCT05675306 study?
This clinical trial studies the following conditions: Childhood Apraxia of Speech.
What interventions are being tested in trial NCT05675306?
The interventions under investigation include: Dynamic Temporal and Tactile Cueing Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT05675306?
This trial is sponsored by Marquette University, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05675306 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Childhood Apraxia of Speech
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI